Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02652130 · ClinicalTrials.gov registry record · Phase 3
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 20
- Study locations
NCT02652130 is a Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease that has completed, run by Mesoblast. The registered enrollment target is 32 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT02652130, a Phase 3 study of Grade B Acute Graft Versus Host Disease and Grade C Acute Graft Versus Host Disease, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 20
- Study locations
Study Summary
Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticosteroid therapy.
Conditions Studied
Interventions
- BIOLOGICAL Remestemcel-L
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- CHOC Children's Hospital of Orange County - Orange
- UCSF Benioff Children's Hospital - San Francisco
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- The Children's Hospital at Montefiore - New York
Colorado
- Children's Hospital Colorado Center for Cancer/Blood Disorders - Aurora
Delaware
- Alfred I. duPont Hospital for Children of the Nemours Foundation - Wilmington
Florida
- Miami Children's Research Institute - Miami
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Michigan
- Children's Hospital of Michigan - Detroit
Mississippi
- University of Mississippi Medical Center - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-10-28 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02652130
The ClinicalTrials.gov registry entry for NCT02652130 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Grade B Acute Graft Versus Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Remestemcel-L is the first listed.
NCT02652130 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT02652130 about?
NCT02652130 is a clinical study titled "Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD". Ongoing safety assessment follow-up to Protocol MSB-GVHD001 (NCT02336230) of remestemcel-L treatment in pediatric participants with acute graft versus host disease (aGVHD), following allogeneic hematopoietic stem cell transplant (HSCT), that have failed to respond to treatment with systemic corticos...
What is the current status of trial NCT02652130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2015-10-28. Estimated completion is 2018-06-15.
What conditions does trial NCT02652130 study?
This clinical trial studies the following conditions: Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease.
What interventions are being tested in trial NCT02652130?
The interventions under investigation include: Remestemcel-L (BIOLOGICAL).
Who is sponsoring clinical trial NCT02652130?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02652130 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Grade B Acute Graft Versus Host Disease
All registered trials for this condition
Grade C Acute Graft Versus Host Disease
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.